Lead Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Collaborators

Age

All ages

Sex

MALE

Healthy Volunteers

No

•In accordance with NICE active surveillance guidelines, men:
•Who have been evaluated using a combination of clinical, bio-chemical, imaging and/or biopsy, within the last 12 months
•With histologically confirmed low or intermediate risk prostate cancer, Gleason score ≤7 (3+4, not 4+3)
•With up to T2a clinical stage tumours
•With pre-treatment PSA ≤20 ng/mL
•Who are willing to participate in optimal active surveillance and provide written informed consent
•With life expectancy of ≥10 years

•Men:
•With unstable angina
•With uncontrolled hypertension
•With recent myocardial infarction (within the past 6 months)
•With pacemakers
•Already undertaking regular physical activity (greater than 90 minutes of moderate intensity exercise, per week) will be excluded
•With any other physical or mental limitation preventing participation in trial assessments
•Participating in other clinical trials which might bias the evaluation of the primary objectives of the present study

Related studies

NCT06787053 · Bladder (Urothelial, Transitional Cell) Cancer, Prostate Cancer

NCT07580196 · Prostate Cancer

NCT06616155 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, and more

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

NCT07181122 · Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer